Multiple Myeloma Management

Published by: UMA MLG
Downloads
Revenue

Description

Bispecific antibodies are a novel mechanism in the management in the relapsed/refractory multiple myeloma. Recognizing the mechanism of these agents as well as preliminary efficacy data is important in considering clinical trials and implementing approved bispecific antibodies in the management of multiple myeloma.
Hide Show More...

Screenshots

Multiple Myeloma Management FAQ

  • Is Multiple Myeloma Management free?

    Yes, Multiple Myeloma Management is completely free and it doesn't have any in-app purchases or subscriptions.

  • Is Multiple Myeloma Management legit?

    Not enough reviews to make a reliable assessment. The app needs more user feedback.

    Thanks for the vote

  • How much does Multiple Myeloma Management cost?

    Multiple Myeloma Management is free.

  • What is Multiple Myeloma Management revenue?

    To get estimated revenue of Multiple Myeloma Management app and other AppStore insights you can sign up to AppTail Mobile Analytics Platform.

User Rating
App is not rated in Italy yet.
Ratings History

Multiple Myeloma Management Reviews

No Reviews in Italy
App doesn't have any reviews in Italy yet.

Store Rankings

Ranking History
App Ranking History not available yet
Category Rankings
App is not ranked yet

Multiple Myeloma Management Competitors

Name
NephRef
Multiple Myeloma Manager
KUCC Clinical Trial Finder
KUCC Clinical Trial Finder
Kyntic
Multiple Myeloma [MM]
From @Point of Care™
Mobile Health Records App
Medical Records
SurvivorNet
florio ITP
inSight AWM CR
Clinical Research for Wound
HealthTree
Cancer Support & Education

Multiple Myeloma Management Installs

Last 30 days

Multiple Myeloma Management Revenue

Last 30 days

Multiple Myeloma Management Revenue and Downloads

Gain valuable insights into Multiple Myeloma Management performance with our analytics.
Sign up now to access downloads, revenue, and more.

App Info

Category
Medical
Publisher
UMA MLG
Languages
English
Recent release
1.0 (1 year ago )
Released on
May 26, 2023 (1 year ago )
Last Updated
1 week ago
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.